by Sue Robbins | Mar 9, 2020 | Migraine
The Food and Drug Administration (FDA) has approved Nurtec™ ODT (rimegepant; Biohaven) for the acute treatment of migraine with or without aura in adults. Nurtec ODT is a calcitonin gene-related peptide receptor antagonist administered via an orally disintegrating...
by Sue Robbins | Mar 9, 2020 | Migraine
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Qtrypta™ (M207) (zolmitriptan intracutaneous microneedle system; Zosano Pharma) for the acute treatment of migraine. Qtrypta delivers zolmitriptan, a selective...
by Sue Robbins | Mar 5, 2020 | Migraine
If you have raging headaches and you spend a lot of time on your smartphone, a new study suggests you might want to put your phone down whenever you can. Researchers found that folks who use their smartphones frequently and have headaches or migraines also tend to...
by Sue Robbins | Mar 2, 2020 | Migraine
In the book “Migraine: A History” (Johns Hopkins University Press), medical historian Katherine Foxhall writes of a disabling disease that has been documented going back thousands of years, though the causes of this neurological disorder are still unclear....
by Sue Robbins | Feb 28, 2020 | Migraine
NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant) for the acute treatment of migraine in adults. Nurtec...
